Bio-Rad Laboratories, Inc. $BIO Shares Sold by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lessened its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 12,211 shares of the medical research company’s stock after selling 124 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Bio-Rad Laboratories were worth $2,982,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of BIO. First Pacific Advisors LP lifted its position in shares of Bio-Rad Laboratories by 136.0% during the 1st quarter. First Pacific Advisors LP now owns 372,555 shares of the medical research company’s stock valued at $90,739,000 after acquiring an additional 214,705 shares during the last quarter. Ariel Investments LLC lifted its position in shares of Bio-Rad Laboratories by 29.3% during the 1st quarter. Ariel Investments LLC now owns 724,660 shares of the medical research company’s stock valued at $176,498,000 after acquiring an additional 164,136 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Bio-Rad Laboratories by 17.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 877,040 shares of the medical research company’s stock valued at $213,608,000 after acquiring an additional 130,921 shares during the last quarter. Mawer Investment Management Ltd. lifted its position in shares of Bio-Rad Laboratories by 14.8% during the 1st quarter. Mawer Investment Management Ltd. now owns 294,879 shares of the medical research company’s stock valued at $71,821,000 after acquiring an additional 37,952 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its position in shares of Bio-Rad Laboratories by 231.8% during the 2nd quarter. Allianz Asset Management GmbH now owns 54,239 shares of the medical research company’s stock valued at $13,089,000 after acquiring an additional 37,893 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 0.4%

NYSE BIO opened at $339.92 on Friday. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $9.20 billion, a PE ratio of 28.98 and a beta of 0.97. The firm’s fifty day simple moving average is $295.35 and its 200-day simple moving average is $262.38.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The business had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. During the same period in the prior year, the business posted $3.11 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BIO has been the subject of a number of recent research reports. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Weiss Ratings reissued a “sell (d+)” rating on shares of Bio-Rad Laboratories in a research note on Tuesday, October 14th. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Royal Bank Of Canada boosted their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Finally, Zacks Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $333.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.